tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Nxera Pharma Gains Milestone Payment in Sleep Disorder Collaboration

Nxera Pharma Gains Milestone Payment in Sleep Disorder Collaboration

Sosei Group (JP:4565) has released an update.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Nxera Pharma has received a $3.5 million milestone payment from Centessa Pharmaceuticals following the initiation of a Phase 2 trial for ORX750, a promising treatment for sleep disorders. This achievement reflects Nxera’s strategic investment and collaboration efforts, potentially enhancing its equity value and future revenue through further milestone payments and royalties.

For further insights into JP:4565 stock, check out TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1